Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Mar 18, 2023
Editas Medicine (EDIT, $8.37) was a top loser this quarter, falling -18.5%

Editas Medicine (EDIT, $8.37) was a top loser this quarter, falling -18.5%

Over the last three months, Editas Medicine (EDIT) has been a top loser in the biotechnology industry, falling by 18.5% to $8.37 per share. This information was gathered by A.I.dvisor, which analyzed 968 stocks in the biotechnology industry for the 3-month period ending March 17, 2023, and found that 60.19% of them demonstrated a downtrend, while only 39.81% exhibited an uptrend.

However, there is some positive news for EDIT as it is currently in an upward trend. The price of EDIT may ascend as a result of having broken its lower Bollinger Band on March 10, 2023. This means that EDIT may jump back above the lower band and head towards the middle band. Traders may consider buying the stock or exploring call options.

It is interesting to note that in 29 out of 32 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. This means that the odds of a continued upward trend are quite high, at 90%.

Despite EDIT's recent losses, the company's potential to impact the biotechnology industry is significant. Editas Medicine is a leading genome editing company that uses CRISPR technology to develop new therapies for genetic diseases. The company's pipeline includes treatments for a range of diseases, including sickle cell anemia, beta-thalassemia, and Duchenne muscular dystrophy.

In addition to its pipeline, Editas Medicine has partnerships with major pharmaceutical companies such as Allergan and Juno Therapeutics. These partnerships help to provide the company with funding and resources to continue its research and development efforts.

Overall, while EDIT may have experienced losses over the last three months, the company's potential for growth is significant. 

Related Ticker: EDIT

EDIT's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for EDIT turned positive on February 20, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 20, 2026. You may want to consider a long position or call options on EDIT as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

EDIT moved above its 50-day moving average on March 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EDIT crossed bullishly above the 50-day moving average on March 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDIT broke above its upper Bollinger Band on March 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.231) is normal, around the industry mean (30.245). P/E Ratio (0.000) is within average values for comparable stocks, (40.902). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.820). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.859) is also within normal values, averaging (315.809).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 26 to 123.47B. VRTX holds the highest valuation in this group at 123.47B. The lowest valued company is KRBPQ at 26.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 24%. SPRC experienced the highest price growth at 569%, while CLDI experienced the biggest fall at -56%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 182%. For the same stocks of the Industry, the average monthly volume growth was 68% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 57
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EDIT showed earnings on March 09, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com
Interact to see
Advertisement
Financial Learning Models (FLMs) and machine learning (ML) to operate at unprecedented speeds. These agents, now optimized for 5-minute (M5) timeframes, have demonstrated extraordinary annualized returns, with the top agent exceeding +160%.
AI-Driven Market Insights A.I.dvisor’s latest analysis compares SPY and VOO, two leading ETFs, revealing near-identical year-to-date (YTD) gains of 9.82% for SPY and 9.87% for VOO, a 99% parity.
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These innovative brokerage agents provide real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced groundbreaking results from its AI Trading Agents, showcasing exceptional performance in real-time trading signals powered by machine learning. Utilizing tick-level brokerage data and precise trade amounts, these agents operate on 5-, 15-, and 60-minute timeframes to provide traders with actionable insights in volatile markets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents. These cutting-edge brokerage agents deliver real-time trading signals powered by machine learning, leveraging tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes. Designed to empower traders with superior insights, the agents have demonstrated exceptional performance, including annualized returns as high as 82%.
#artificial_intelligence
The financial markets have undergone a profound transformation in recent years, driven by the integration of artificial intelligence (AI) into trading strategies. As a financial analyst, writer, and AI specialist, one observes that AI trading agents represent a pinnacle of this evolution, blending machine learning algorithms with real-time data analysis to execute trades with unprecedented precision.
#artificial_intelligence
AI trading represents a revolutionary shift in how financial markets operate, combining artificial intelligence, machine learning, and sophisticated algorithmic trading strategies to execute trades with unprecedented precision and speed.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced exceptional trading results from its AI Trading Agent focused on Hubbell Incorporated (HUBB). The agent, operating on a 5-minute timeframe, delivered a +105% annualized return, starting from an initial balance of $100,000.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technology, today announced the launch of its advanced AI Trading Agents, delivering real-time trading signals and sophisticated money management for retail and institutional traders. Powered by Financial Learning Models (FLMs) and machine learning, these agents operate across 5-, 15-, and 60-minute timeframes, achieving annualized returns of up to 145% on select portfolios.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, today announced the exceptional performance of its AI Trading Agents, achieving annualized returns of up to 162%, profitable trade percentages as high as 90.51%, and a robust profit factor across multiple assets.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technology, proudly announces the exceptional performance of its AI Trading Agents, delivering annualized returns of up to 188% on a 5-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial tools, today announced the launch of its advanced Pattern Search Engine (PSE), a revolutionary platform that scans 39 distinct trading patterns across stocks, penny stocks, ETFs, crypto, and forex.
#artificial_intelligence
AI trading bots represent the pinnacle of financial technology innovation, transforming how traders and investors interact with global markets.
#artificial_intelligence
As a financial analyst, writer, and AI specialist, I've always pushed for innovations that merge artificial intelligence with actionable trading tools. In the fast-paced world of modern markets, where volatility demands quick decisions, Tickeron's new "My Trades Aggregator (from AI Robots Followed)" aggregator stands out as a revolutionary feature.
#artificial_intelligence#trading
Tickeron, a leading provider of AI-driven trading solutions, is thrilled to announce the exceptional performance of its AI Trading Agents, delivering outstanding results across multiple high-profile stocks.
#artificial_intelligence
Tickeron, a leader in AI-driven financial technologies, today announced groundbreaking results from its AI Crypto Trading Virtual Agents. These innovative tools provide real-time trading signals, integrated money management, and customizable balances, all powered by advanced machine learning algorithms operating on 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
Tickeron, a leading innovator in AI-driven financial technologies, today announced the launch of its advanced AI Trading Brokerage Agents. These cutting-edge tools deliver real-time trading signals powered by machine learning, utilizing tick-level brokerage data and precise trade amounts across 5-, 15-, and 60-minute timeframes.
#artificial_intelligence
This remarkable rally represents far more than typical market volatility – it signals a fundamental transformation in investor sentiment toward AI connectivity infrastructure and the critical role of semiconductor-based solutions in enabling next-generation artificial intelligence systems
Tickeron, a leader in AI-driven financial tools, today announced the launch of its comprehensive subscription package combining AI Trading Robots for cryptocurrencies with Real-Time Patterns (RTP) analysis.
#artificial_intelligence
Kinross Gold Corporation (KGC), a leading Canada-based gold producer, yielded approximately 2.1 million gold equivalent ounces in 2024.
#artificial_intelligence